TP53I11: A Promising Drug Target and Biomarker for Tumor Progression

Target Name: TP53I11

NCBI ID: G9537

TP53I11

TP53I11: A Promising Drug Target and Biomarker for Tumor Progression

Introduction

Tumor progression is a critical event in the development and treatment of cancer. The regulation of cell growth and apoptosis by the tumor suppressor protein p53 is a key factor in preventing tumor growth and progression. p53I11 is a 11-kDa tumor protein that is expressed in various tissues and is a potent inhibitor of p53 activity. The deregulation of p53I11 has been implicated in the development and progression of many types of cancer. Therefore, targeting p53I11 has emerged as a promising strategy for cancer treatment.

Drugs that target p53I11 have the potential to inhibit tumor growth and progression by activating p53 activity. p53I11 has been shown to play a critical role in the regulation of cell cycle progression and apoptosis, and has been linked to the efficacy of many anti-cancer drugs . Therefore, targeting p53I11 with drugs that enhance p53 activity could be a promising strategy for cancer treatment.

Expression and Localization of TP53I11

TP53I11 is a 11-kDa protein that is expressed in various tissues, including muscle, kidney, liver, and breast cancer. It is predominantly expressed in the cytoplasm and is also found in the endoplasmic reticulum (ER) and the nuclear envelope (NE) . TP53I11 is localized to the nuclear envelope and is associated with the perinucleus region of the nuclear DNA.

TP53I11 has been shown to interact with various nuclear proteins, including p53, p21, and p56. These interactions may play a role in the regulation of p53 activity and the control of cell growth and apoptosis.

Function and regulation of TP53I11

TP53I11 is a potent inhibitor of p53 activity and has been shown to inhibit the activity of both wild-type and mutant p53 in cell culture and animal models of cancer. The inhibition of p53I11 activity by TP53I11 has been shown to increase the activity of the p53 wild-type protein and enhance the inhibition of the p53 mutant protein.

In addition to its role in inhibiting p53 activity, TP53I11 has also been shown to regulate the expression of other genes involved in cell growth and apoptosis. For example, TP53I11 has been shown to inhibit the activity of the myogenic factor Myf, which is involved in the development of muscle tissue.

Targeting TP53I11

The inhibition of TP53I11 activity by drugs has the potential to be a promising strategy for cancer treatment. One approach to targeting TP53I11 is to use small molecules that can inhibit its activity.

Various small molecules have been shown to inhibit the activity of TP53I11. One of the most promising approaches is the use of inhibitors of DNA-protein binding, which can enhance the activity of TP53I11 by disrupting its interactions with p53 and other nuclear proteins.

Another approach to targeting TP53I11 is the use of small molecules that can alter the localization and stability of TP53I11. For example, inhibitors of the protein-protein interaction (PPI) network, which can disrupt the interactions between TP53I11 and other nuclear proteins, may be effective in inhibiting TP53I11 activity.

Conclusion

TP53I11 is a tumor protein that plays a critical role in the regulation of cell growth and apoptosis. Its inhibition

Protein Name: Tumor Protein P53 Inducible Protein 11

The "TP53I11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TP53I11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets